AMC-303 is under clinical development by Amcure and currently in Phase I for Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Head And Neck Cancer Squamous Cell Carcinoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AMC-303’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AMC-303 is under development for the treatment of advanced and metastatic epithelial tumors such as pancreatic cancer, gastric cancer, colorectal cancer, breast cancer, head and neck cancer squamous cell carcinoma, squamous non-small cell lung carcinoma, esophageal tumor, cervical cancer, esophageal cancer. It is administered through intravenous route. The therapeutic candidate is a synthetic peptide. It acts by targeting CD44v6.
amcure is a biopharmaceutical company that discovers and develops therapeutics for the treatment of cancer. The company develops peptide-based compounds for the treatment of metastatic forms of cancer. Its lead candidate, AMC303 is used for the treatment of metastatic epithelial tumors such as colorectal, breast, lung, pancreatic, head and neck; and gastric cancers. Its AMC303 inhibits the growth of CD44v6, a co-receptor used for signaling through multiple cellular pathways that are involved in promoting tumor growth, angiogenesis and the development of metastases. The company operates through partnerships and grants with education and research organizations. Amcure is headquartered in Eggenstein-Leopoldshafen, Baden-Wurttemberg, Germany.
For a complete picture of AMC-303’s drug-specific PTSR and LoA scores, buy the report here.